News
05-26-2011, 03:20 AM
Boehringer Ingelheim Pharmaceuticals, Inc. will present new phase Ib data at the 2011 American Society of Clinical Oncology annual meeting in Chicago that indicates combining its investigational therapy afatinib with cetuximab at the maximum tested dose controlled disease in all (n=22) treated epidermal growth factor receptor (EGFR)-mutation positive patients with non-small cell lung cancer who developed acquired resistance to treatment with a reversible EGFR tyrosine kinase inhibitor.
More... (http://www.news-medical.net/news/20110526/Boehringer-Ingelheims-new-afatinib-cetuximab-phase-Ib-data-in-NSCLC-presented-at-ASCO-2011.aspx)
More... (http://www.news-medical.net/news/20110526/Boehringer-Ingelheims-new-afatinib-cetuximab-phase-Ib-data-in-NSCLC-presented-at-ASCO-2011.aspx)